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Background: Aberrant DNA methylation profiles are a characteristic feature of almost all types of cancers including
hepatocellular carcinoma (HCC) and play an important role in carcinogenesis. In spite of the accumulating evidence
that suggests appearance of such aberrations at precancerous stages, very little effort has been invested to
investigate such possible methylation events in patients at risk of developing HCC i.e. those suffering from chronic
hepatitis C virus (HCV) infection and liver cirrhosis (LC). We reasoned that such an analysis could lead to the
identification of novel predictive biomarkers as well as potential drug targets.
Methods: Promoter methylation status of two Wnt inhibitors SFRP2 and DKK1 was quantitatively analyzed by bisulfite
pyrosequencing in a series of liver biopsy samples. These biopsies were collected from HCV-infected individuals
suffering from chronic hepatitis (CH; n = 15), liver cirrhosis (LC; n = 13) and hepatocellular carcinoma (HCC; n = 41).
DNA isolated from infection free normal livers (N; n =10) was used as control.
Results: Our analysis revealed that both of the genomic loci were significantly hypermethylated in CH patients’ livers
as compared to normal controls (p = 0.0136 & 0.0084 for SFRP2 and DKK1, respectively; Mann–Whitney U test). DNA
methylation levels for both loci were also significantly higher in all the diseased cohorts as compared to normal
controls (p < 0.0001 and = 0.0011 for SFRP2 and DKK1, respectively; Kruskal-Wallis test). However, a comparison
between three disease cohorts (CH, LC & HCC) revealed no significant difference in levels of DNA methylation at
DKK1 promoter. In contrast, a progressive increase in DNA methylation levels was observed at the SFRP2 promoter
(i.e. N < CH & LC < HCC).
Conclusion: This study demonstrated that in HCV infected liver tissues hypermethylation at promoter regions of key
cancer related genes SFRP2 and DKK1, appears early at CH and LC stages, long before the appearance of HCC.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and is the third leading cause of cancer re-
lated mortality worldwide. According to International
Agency for Research on Cancer (IARC) reports 696,000
people died of liver cancer in the year 2008 alone [1]. Mul-
tiple factors have been associated with HCC, however
hepatitis B & C virus (HBV and HCV) infections are* Correspondence: hamzamgondal@gmail.com
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unless otherwise stated.considered to be the major underlying etiology, as to-
gether these viruses account for more than two-thirds of
HCC cases worldwide [2]. With around 2 billion people
infected with HBV worldwide, of which approximately
350 million are chronic HBV carriers [3], and 170 million
infected with HCV [4], HCC poses a major health concern
globally. Recent estimates show that at least 15 million
people in Pakistan are infected either with HBV or HCV
(2.5% and 4.8% of the total population, respectively) [5,6],
and are hence at an increased risk of developing HCC.
HCV induced HCC follows a progressive course of de-
velopment from hepatitis to HCC in most cases (i.e.,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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various aspects of this complicated pathogenesis have
been interrogated, its underlying mechanism(s) remain
elusive. Since HCV is different from HBV, as it harbors an
RNA genome that does not integrate in the host cell gen-
ome [8], therefore, alternative or indirect models of HCV
mediated hepatic oncogenesis have been proposed. It has
been suggested that immune mediated chronic liver
damage induced by persistent HCV infection, and the
accompanying compensatory hepatic regeneration by pro-
liferation and cell division, might culminate in a micro-
environment that is conducive for increased mutagenic
rates [9]. However, the development of HCC in transgenic
mice expressing the HCV core gene alone suggests that al-
ternative mechanisms may also be involved [10]. It has
been proposed that HCV induces hepatocarcinogenesis
via host and viral protein interactions [11]. A number of
studies using mice engineered to carry various HCV genes
have demonstrated that their respective expression might
promote HCC by several mechanisms including inhibition
of apoptosis, pro-oncogenic pathway activation and in-
creased production of reactive oxygen species [11]. While
these studies highlight the role of HCV proteins as tumor
promoters, it remains an open question that whether or
not intracellular expression of these proteins triggers he-
patic neoplasm.
Alterations in the normal DNA methylation patterns are
found ubiquitously in most types of cancers and play a
fundamental role in genesis of cancers including HCC
[2,11-13]. For example, activation of canonical Wnt/ß-
Catenin pathway which is implicated in almost all types of
cancers [14-19], has often been attributed to epigenetic
silencing of Wnt inhibitors like SFRP2 and DKK1 [20-24].
Although whole genome sequencing of HCC tissues has
found etiology-specific recurrent mutation patterns as well
as key pathways that might be altered as a result of these
genetic alterations [14,15], absence of such mutational ab-
errations in precancerous lesions indicates that they might
appear late in this multistep carcinogenesis. In contrast, it
has been suggested that epigenetic aberrations such as his-
tone modification and/or DNA methylation might serve
as key triggers that initiate carcinogenesis [25]. Some
studies have reported the promoter DNA hyperme-
thylation of tumor suppressor genes in pre-cancerous le-
sions like chronic hepatitis, cirrhosis in liver [26,27] and
atypical hyperplasia in breasts [28], highlighting the early
onset of epigenetic dysregulations in multistep oncogenic
processes.
Aberrant DNA methylation patterns are a promising
biomarker for early detection and assessment of future
cancer risk in high risk populations owing to their early
appearance in carcinogenesis [29]. However, very few stu-
dies exist in which methylome alterations in liver tissues
obtained from HCV infected non-cancer patients (CH &LC) have been explored [30]. Moreover, in spite of the
near ubiquitous Wnt pathway activation [14,15] and pos-
sible epigenetic silencing of Wnt inhibitors, especially
SFRP2 and DKK1 in HCC [21-24], very limited data is
available regarding methylation of these loci in HCV
infected non-cancerous patients. To the best of our know-
ledge, no studies till date have systematically analyzed
promoter methylation levels of these important Wnt
inhibitors (SFRP2 & DKK1) in HCV infected CH & LC
patients (without cancer) and compared these methylation
levels with infection free normal liver tissues as well as
HCC.
In this study, we tried to fill this gap by carrying out
DNA methylation analysis of SFRP2 and DKK1 promoter
regions, using a series of biopsies obtained from HCV in-
fected CH and LC patients. These patients did not exhibit
any signs of presence of tumorous mass on their livers.
DNA obtained from infection free normal liver tissues as
well as biopsy samples from an independent group of
HCV-positive HCC patients were also included for com-
parative analysis. Our results demonstrate that both pro-
moters experience elevated levels of DNA methylation in
HCV infected CH, LC and HCC patients as compared to
normal controls, indicating that promoters hypermethyla-
tion of these key cancer related genes (SFRP2 & DKK1) is
an early event in precancerous HCV infected liver tissues.
Results
Patient characteristics
Among the 15 chronic hepatitis patients included in this
study, histopathological analysis revealed minimum or no
fibrosis in all collected samples. Out of the 15 suspected
liver cirrhosis patients, 13 were finally selected for this
study as histopathology reports for 2 patients were not
available. Similarly, out of the 50 HCC patients initially
biopsied, only 41 were included in final DNA methylation
analysis after histopathological analysis confirmed that
biopsied tissue corresponded to tumorous growth. Owing
to co-morbidities that may arise in advanced HCC pa-
tients and the resulting difficulties and contraindications
related to biopsy procedure, HCC patient group was
largely uniform in its composition with regard to tumor
stage. All the biopsied patients had 1–3 solitary tumorous
growths that were ≤ 4 cm in size (Stage 0/A, BCLC staging
system [31]). α-Fetoprotein levels were highly variable
and correlated poorly with stage or severity of disease.
Basic demographic and clinicopathological data of patient
groups are shown in Tables 1 and 2, respectively.
Promoter DNA methylation analyses of normal liver
samples
The pyrosequencing based assays employed in our study
were able to quantify methylation at each of the 5 con-
secutive CpG positions in both of the promoter regions







(n = 15) (n = 13) (n = 41)
Age (years)
< 40 07 04 03
40-60 08 07 27
> 60 00 02 11
Gender
Male 09 10 32
Female 06 03 09
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Our overall analysis revealed that both of the target re-
gions generally remained hypomethylated in normal livers.
The baseline methylation levels in normal controls for
SFRP2 promoter region ranged from 5.4 to 9.7 (mean ±
SD, 7.4 ± 1.5; Figure 3). Similarly average percentage
methylation across 5 CpG positions investigated for DKK1
promoter sequence ranged from 4.6 to 12.1 (mean ± SD,
8.1 ± 2.6; Figure 4).
SFRP2 promoter region shows a progressive
hypermethylation pattern in multistep
hepatocarcinogenesis
SFRP2 promoter methylation level was analyzed in liver
biopsy samples obtained from HCV-positive patients suf-
fering from chronic hepatitis (n = 15) or liver cirrhosis
(n = 13), without any concomitant tumorous growth on
their livers. It was observed that levels of methylation at
the interrogated loci were significantly higher in both
chronic hepatitis as well as liver cirrhosis groups as com-
pared to normal livers (p = 0.01 & 0.0004, respectively;Table 2 HCC patients’ clinicopathological features
Variable Number of patients










< 20 ng/ml 06
20-400 ng/ml 23
> 400 ng/ml 12Mann–Whitney test). Average percentage methylation
across the 5 consecutive CpG positions analyzed ranged
from 5.4 to 16 (mean ± SD, 10.5 ± 3.2) for chronic hepa-
titis samples while for samples obtained from cirrhotic
livers the values ranged between 7.6 and 15.2 (mean ± SD,
11.8 ± 2.2).
While values for all other tissue types varied between a
narrow range samples obtained from HCC patients exhi-
bited a high variance in methylation percentage (co-
efficient of variation 52.5%). Average percent methylation
in HCC samples ranged between 7.6 and 52 (mean ± SD,
27.5 ± 14.5). A comparison of HCC group with other
groups (i.e., N, CH & LC) revealed that HCC group shows
a significantly higher level of methylation in comparison
to all the other groups (HCC Vs LC, p = 0.001), p values
computed by Mann–Whitney test for group wise com-
parison are shown in Table 3 (also see Figure 4).
DKK1 promoter hypermethylation is an early event but
does not show progressive increase in HCV mediated
multistep hepatocarcinogenesis
DKK1 promoter region was also found to be hyper-
methylated in liver biopsies obtained from HCV infec-
ted patients at various stages of disease progression as
compared to normal controls (p = 0.001; Kruskal-Wallis
test). Mann–Whitney test was employed to compare the
diseased groups (CH, LC, HCC), which revealed that no
significant differences in level of methylation between
them are found for DKK1 promoter, in contrast to
SFRP2 (see Figure 2 and Table 3).
Discussion
DNA methylation is considered as an important con-
tributor to the development of HCC. However in spite
of the growing body of evidence which suggests that it is
an early event in hepatocarcinogenesis [32-35], identifi-
cation of important methylation events in diseased con-
ditions of liver (CH & LC), which might predispose
affected patients to the development of HCC later in life,
has not been studied extensively. Recent cell culture
studies point towards a possible direct role of HCV core
protein in modulating host cell methylome [36,37].
Therefore it will be important to investigate whether pa-
tients infected with HCV, yet without HCC, harbor any
aberrations in DNA methylation patterns in their livers.
Most of the studies aiming to identify early changes in
methylation patterns make use of histologically non-
malignant liver tissues obtained from HCC patients
[32,33,38,39]. However, as viral induced HCC develops
after decades of infection, this strategy might not prove
to be adequate because it will be difficult to differentiate
between “driver” and “passenger” methylation [40] aber-
rations in such long infected hepatocytes, even if they
appear histologically non-malignant. Therefore, in this
Figure 1 Representative pyrograms of SFRP2 promoter DNA methylation analysis. (a) Normal liver samples (b) Chronic hepatitis (c) Cirrhotic
liver tissue (d) HCC tissue specimen.
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tions in HCV infected non-cancerous patients (CH &
LC) with the aim to identify DNA methylation markers
which can be exploited for surveillance and carcinogenic
risk estimation in high risk populations as well as deve-
lopment of novel drug targets.
Our analysis revealed that both of the Wnt inhibitors
included in this study display an increased level of
methylation in their promoter regions in HCV infected
patients even at the very early stages of hepatic disease
(Figures 4 & 2, Table 3). Chronic hepatitis tissue samples
exhibited significantly higher levels of methylation as
compared to normal controls (p = 0.0136 & 0.0084 forSFRP2 & DKK1 respectively, Mann–Whitney U test).
CH patients included in our study had minimal liver
damage and were ideal candidates for interferon therapy.
Occurrence of promoter hypermethylation in such early
stage liver disease, points to the fact that this epigenetic
aberration might occur much earlier than previously
thought [33]. Similarly, the other non-cancerous disease
cohort i.e. LC also showed significantly higher methy-
lation levels as compared to normal controls (see Table 3
for more details). It is important to note here that al-
though the methylation percentages in CH and LC groups
differed significantly from normal controls, the maximum
observed percent methylation did not exceed 16% for both
Figure 2 Representative pyrograms of DKK1 promoter DNA methylation analysis. (a) Normal liver samples (b) Chronic hepatitis (c) Cirrhotic
liver tissue (d) HCC tissue specimen.
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apparently “low” methylation can be attributed to the fact
that sample DNA was obtained from a heterogeneous
population of infected and non-infected hepatocytes. As
previous studies have reported that only a very small per-
centage of hepatocytes (2-30%) are actually infected with
HCV [41,42], the said “low” methylation observed in ourFigure 3 SFRP2 promoter DNA methylation analysis. Box and whiskers
promoter region. Methylation levels increased in a progressive fashion that
to HCC. Significance of difference in methylation level calculated by Mann–
information about group-wise comparison, see Table 3. N = Normal, CH = Cexperiments appears to be in agreement with findings of
these studies.
Interestingly SFRP2 promoter exhibited a pattern of
progressive increase in DNA methylation that coincided
with the various stages of liver disease, i.e. chronic hepa-
titis and cirrhotic samples exhibited methylation levels
which were statistically higher than normal controls (N Vsrepresentation of average DNA methylation percentages at SFRP2
coincided with the progression of liver disease from chronic hepatitis
Whitney test (p values) are shown where relevant. For more detailed
hronic Hepatitis, LC = Liver Cirrhosis, HCC = Hepatocellular Carcinoma.
Figure 4 DKK1 promoter DNA methylation analysis. Average methylation percentages in diseased cohorts were significantly higher than normal
livers (p < 0.05, Kruskal-Wallis test). However the three diseased cohorts did not differ from each other significantly. (See Table 3 for more details).
N = Normal, CH = Chronic Hepatitis, LC = Liver Cirrhosis, HCC = Hepatocellular Carcinoma.
Umer et al. Virology Journal 2014, 11:117 Page 6 of 10
http://www.virologyj.com/content/11/1/117CH p = 0.0136, N Vs LC p = 0.0084, Mann Whitney-U
test). Similarly, HCC sample cohort showed significantly
higher methylation as compared to chronic hepatitis as
well as liver cirrhosis samples (CH Vs HCC p < 0.0001, LC
Vs HCC p = 0.0013). This apparent increasing trend might
be because promoter methylation mediated silencing of
SFRP2 at the early stages of liver disease provides a defini-
tive selective advantage to affected cells and hence helping
in their clonal expansion [30].
One striking observation that emerged from our results
was that although DKK1 promoter methylation was found
to be significantly higher in all the three diseased groups as
compared to normal controls (p = 0.001; Kruskal-Wallis
test), the three said groups did not differ from each other
considerably (See Table 3 for details). Similar results were
obtained in an earlier study by Yang et al., [23] which re-
ported that DKK1 promoter methylation in HCC tissues
did not differ significantly from surrounding non-tumor tis-
sue or from independent cirrhotic liver samples. However,Table 3 Comparison of patient groups for significance of
difference in methylation
Comparison SFRP2 DKK1 Significance
SFRP2 DKK1
Normal vs Chronic hepatitis 0.0136 0.0084 Yes Yes
Normal vs Liver cirrhosis 0.0004 0.0039 Yes Yes
Normal vs HCC <0.0001 <0.0001 Yes Yes
Chronic hepatitis vs Liver cirrhosis 0.2310 0.6784 No No
Chronic hepatitis vs HCC <0.0001 0.2832 Yes No
Liver cirrhosis vs HCC 0.0013 0.7462 Yes No
Table 3 summarizes the group wise comparisons carried out using non parametric
two tailed Mann–Whitney U test.to the best of our knowledge, it is for the first time that
“baseline” methylation in completely normal liver tissues
has been reported and compared with that of various dis-
ease cohorts. Significance of this comparison is apparent
from our own results where we observed a disease de-
pendent hypermethylation as well as those of Yang et al.
because the said study also found a certain level of hyper-
methylation in DKK1 promoter in HCC free LC patients
(See Figure 3 in the corresponding reference) [23]. Our re-
sults speak strongly in favor of use of infection free normal
controls in order to put observed methylation percentages
in true context.
In a recent study by Nishida et al. [30], a subset of early
HCC related TSGs (HIC1, GSTP1, SOCS1, RASSF1,
CDKN2A, APC, RUNX3, and PRDM2) were also found
to be hypermethylated in HCV infected CH patients.
However, interestingly SFRP2 promoter methylation was
only found in highly progressed HCCs and hence was not
analyzed in non-cancerous HCV infected patients. In
contrast, our results demonstrate that SFRP2 promoter
exhibits hypermethylation in early HCCs as well as HCV
infected non-cancerous (CH and LC) samples. These con-
flicting observations regarding SFRP2 promoter methyla-
tion indicate epigenetic as well as genetic heterogeneity
that is characteristic of all cancers in general including
HCC [43].
Previous in vitro [36,37] and in vivo studies [44] as
well as our own results point out towards a possible
direct role of HCV infection and/or intracellular expres-
sion of HCV genes in modulating host cell methylome.
Although the exact mechanism underlying this possible
effect of HCV infection on host epigenome is still poorly
understood, evidence has started to emerge which can
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phenomenon. An earlier study reported the promoter
hypermethylation mediated down regulation of E-cadherin
by HCV core protein in cultured hepatoma cells [36].
Quan et al. [37] proposed that HCV core causes epigenetic
silencing of Wnt inhibitor SFRP1 by modulating the ex-
pression and binding of histone deacetylase-1 (HDAC1)
and DNA methyltransferase-1 (Dnmt1). In a recent study
Okamoto et al. [44] demonstrated that HBV or HCV in-
fected mice with humanized livers exhibit a time depen-
dent genome wide hypermethylation at various gene
promoters. The authors claimed that ROS production by
innate immune system components like natural killer
T-cells contributes to the development of this aberrant
methylation profile. Further studies will be needed to
explicitly elucidate the possible methylome modulating
properties of various HCV proteins. Moreover, compre-
hensive genome wide analysis of HCC predisposing condi-
tions (CH & LC) is also highly imperative in order to
establish a detailed methylation map of such diseased tis-
sues which could be further exploited as biomarker for
cancer risk prediction and identification of novel drug tar-
gets for prevention of HCC development.
Conclusions
Our results demonstrate that both promoters of Wnt in-
hibitor genes (SFRP2 & DKK1) experience a significantly
elevated levels of DNA methylation in HCV infected non-
cancerous disease cohorts (CH & LC) as well as HCC
patients as compared to normal controls. These results
correlate that promoters hypermethylation of these key
cancer related genes (SFRP2 & DKK1) is an early event in
precancerous HCV infected liver tissues. While SFRP2
locus becomes increasingly hypermethylated as the disease
progresses from CH to HCC, a similar progressive trend
was not observed for DKK1 promoter region. Identification
of such methylation events in patients at risk of developing
HCC later in life might help in development of novel pre-
dictive biomarkers as well as cancer prevention strategies.
Data presented in this study points towards a possible
direct role that HCV infection itself or the intracellular
expression of various HCV genes might play in modulating
the host cell methylation pattern, however further stu-
dies will be needed to clearly elucidate the underlying
mechanism.
Study limitations
In this study, we have not demonstrated the alterations
in gene expression which might be correlated with our
reported promoter hypermethylation. However, as asso-
ciation of promoter CpG island hypermethylation with
silencing of corresponding gene is now an established
fact [45] and many studies conducted in the past have
demonstrated such a correlation for our target genes i.e.SFRP2 & DKK1 [20,24]. Therefore, we can rightly expect
a similar functional implication of DNA hypermethyla-
tion, as observed in our study.
Theme of this study was to check the promoter hyper-
methylation of cancer related target genes (SFRP2 &
DKK1) in HCV infected chronic hepatitis, liver cirrhosis
and HCC patients and compare that with infection free
normal livers. Therefore, exclusion of HBV samples does
not affect the overall theme of this study i.e. aberrations
in epigenome start to appear in pre-cancerous stages of
cancer causing conditions (chronic HCV infection). A
separate study, after including the statistically represen-
tative number of HCV and HBV infected liver samples
of various disease cohorts, may prove useful to further
elucidate the underlying mechanism involve in promoter
hypermethylation of Wnt inhibitors (SFRP2 & DKK1).
Methods
Patients
This study was conducted in collaboration with Liver
Center, Faisalabad and Punjab Medical College, Faisalabad.
The study was approved by Institutional Ethical Review
Committee as well as Ethical Committees of collabo-
rating centers. Infection status of patients initially re-
cruited was confirmed by quantitative HBsAg ELISA
(Alpha Diagnostic, Texas, USA) and in house qualitative
reverse transcription PCR for HCV RNA as described
previously [46]. Only HCV positive patients were in-
cluded for further study. Patients having HBV infection
as well as with HBV & HCV co-infections were ex-
cluded. Ultrasonographic examination along with liver
function tests was used to initially assess the extent and
stage of liver disease. Final grouping of patients in
various diseased cohorts was done based on histopa-
thological analysis (see below). As an additional diag-
nostic parameter, α-Fetoprotein levels in the serum of
HCC patients were also determined. Diabetic patients
(HbA1c level ≥ 1% above the normal range) and patients
with fatty liver disease or marked ascites were also ex-
cluded. All patients were tested for possible impaired
hemostasis and platelet count. Individuals with PT-INR
above 1.5 and platelet count less than 150,000/μl were
also not subjected to percutaneous biopsy proce-
dure [47]. A total of 80 liver biopsies were obtained
(CH = 15, LC = 15, HCC = 50) between the years 2009
and 2011 from the patients visiting and/or admitted at the
collaborating center. Genomic DNA obtained from sub-
jects who had died in accidents and had otherwise his-
tologically normal livers and were free from any of the
hepatitis virus infections was used as normal control.
These DNA samples were a kind gift from Professor
Magnus Ingelman-Sundberg, Section of Pharmacoge-
netics, Department of Physiology and Pharmacology,
Karolinska Institutet, Stockholm, Sweden.
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After obtaining written informed consent, percutaneous
liver biopsies were collected using 18-20G semi-automatic
Trucut type biopsy needles (STERICUT® TSK, Japan) un-
der real-time ultrasound guidance by a specialized ultraso-
nologist according to AASLD guidelines [47]. The biopsy
tissue was immediately transferred to PBS solution in
sterile containers. The containers were sealed, placed on
ice and then quickly transferred to the lab.
Histopathological analysis of liver biopsies and grouping
of diseased cohorts
Patients were divided into three diseased cohorts; Chronic
Hepatitis (CH), Liver Cirrhosis (LC) & Hepatocellular
Carcinoma (HCC) based on histopathological analysis of
liver biopsies. Biopsies were graded/scored using various
different scoring systems, depending on the origin of sam-
ple. Chronic hepatitis samples were scored using modified
HAI [48] while for biopsies showing fibrosis, METAVIR
scoring system was used [49]. Only those fibrosis samples
were finally included in DNA methylation analyses which
showed METAVIR fibrosis score 3–4. HCC tissues were
graded based on the degree of tumor differentiation
(poorly, moderately & well differentiated).
Extraction of genomic DNA from liver biopsy samples
Under sterile conditions a small piece from liver biopsy
tissue was cut using a sterile surgical blade. The cut piece
measured less than ¼th of the total length of biopsy tissue.
DNA was isolated using PureLink® Genomic DNA Mini
Kit (Invitrogen™) as per manufacturer’s instructions. Lar-
ger tissues were fine minced into smaller pieces using
sterile scalpel blades. Lysate was prepared by incubating
samples at 55°C for 4–10 hours (depending on the size of
tissue) in 180 μl PureLink™ Genomic Digestion Buffer
(Invitrogen™) in the presence of 20 μl Proteinase-K
solution (supplied with the kit). An additional 20 μl
Proteinase-K solution (20 mg/ml) was added to the mix
after 4 hours of incubation. DNA was eluted in 50 μl elu-
tion buffer supplied with the kit.
Bisulfite conversion and PCR amplification of target
regions
Genomic DNA isolated from liver biopsy tissue or that
obtained from normal livers (250-500 ng) was used in a
20 μl bisulfite conversion reaction using EpiTect® Bisulfite
Kit (Qiagen, Valencia, CA) as per manufacturer’s instruc-
tions. DNA was eluted in 20 μl buffer EB and stored
at −20°C until further use. Bisulfite converted DNA
(1–2 μl) was used in PCR amplification of target regions,
which was carried out using PyroMark PCR Kit (Qiagen,
Valencia, CA) in a 25 μl reaction volume. A 182 bp region
corresponding to SFRP2 promoter region was amplified
using primers (Biomers GmbH, Ulm, Germany) reportedearlier [50]. SFRP2 reaction mix also included 5 μl Q
Solution (supplied with kit). A 161 bp region corres-
ponding to DKK1 promoter region was amplified using
Hs_DKK1_01_PM PyroMark CPG assay (Qiagen, Valencia,
CA). Reverse primer in both of the cases was biotinylated.
Typically ~5 μl of PCR product were analyzed by electro-
phoresis using a 2% agarose gel prepared in 1X TAE.
Bisulfite pyrosequencing
Biotinylated PCR products were immobilized on strepta-
vidin-coated sepharose beads (GE Healthcare). The im-
mobilized PCR product was rendered single-stranded on
PyroMark Q24 Vacuum Workstation according to manu-
facturer’s instructions and finally annealed to sequencing
primer (final concentration 0.3 μM) by heating at 80°C for
2 min followed by incubation for at least 5 minutes at
room temperature [51]. Pyrosequencing reaction was car-
ried out on PyroMark Q24 System. The assay design and
analysis of results was carried out using PyroMark Q24
software (version 2.0.6).
Statistical analysis
Average DNA methylation data (as percent) was analyzed
with GraphPad Prism V5.0 (GraphPad Software, San
Diego, CA). Significance of difference in percent methyla-
tion between diseased cohorts and normal was calculated
by nonparametric one way analysis of variance (Kruskal-
Wallis test). Group-wise comparisons of percent average
methylation between different diseased groups as well as
between diseased groups and normal liver tissues were
carried out by Mann–Whitney U test.
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